Mutations in K-ras and epidermal growth factor receptor expression in Korean patients with stages III and IV colorectal cancer

International Journal of Surgical Pathology

Volumn 19, Issue 2, 2011, Pages 145-151

  Lee, Won Suk ^a   Baek, Jeong Heum ^a   Lee, Jung Nam ^a   Lee, Woon Kee ^a  

^a Gachon University   (South Korea)

Author keywords

colon neoplasm; epidermal growth factor receptor; K ras

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KOREA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; SINGLE STRAND CONFORMATION POLYMORPHISM; SOMATIC MUTATION; SURVIVAL TIME; COLORECTAL TUMOR; GENETICS; MUTATION;

ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79953898859     PISSN: 10668969     EISSN: 19402465     Source Type: Journal    
DOI: 10.1177/1066896911400411     Document Type: Article

References (36)

1. Goh KL, Quek KF, Yeo GT, et al. Colorectal cancer in Asians: a demographic and anatomic survey in Malaysian patients undergoing colonoscopy. Aliment Pharmacol Ther. 2005 ; 22: 859-864. (Pubitemid 41564366)
2. Kim DH, Ahn YO Molecular epidemiology of colon cancer. Cancer Res Treat. 2004 ; 36: 93-99.
3. Vogelstein B., Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988 ; 319: 525-532.
4. Albitar M., Yeh C., Ma W. K-ras mutations and cetuximab in colorectal cancer. N Engl J Med. 2009 ; 360: 834.
5. Bengala C., Bettelli S., Bertolini F. et al. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann Oncol. 2009 ; 20: 469-474.
6. Dougherty U., Sehdev A., Cerda S., et al. Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model. Clin Cancer Res. 2008 ; 14: 2253-2262. (Pubitemid 351559573)
7. Kreeger PK, Mandhana R., Alford SK, Haigis KM, Lauffenburger DA RAS mutations affect tumor necrosis factor-induced apoptosis in colon carcinoma cells via ERK-modulatory negative and positive feedback circuits along with non-ERK pathway effects. Cancer Res. 2009 ; 69: 8191-8199.
8. Lea IA, Jackson MA, Dunnick JK Genetic pathways to colorectal cancer. Mutat Res. 2009 ; 670: 96-98.
9. Ogino S., Meyerhardt JA, Cantor M., et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res. 2005 ; 11: 6650-6656. (Pubitemid 41339006)
10. Nagahara H., Mimori K., Ohta M., et al. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res. 2005 ; 11: 1368-1371. (Pubitemid 40315215)
11. Schubbert S., Shannon K., Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007 ; 7: 295-308. (Pubitemid 46480970)
12. Shaw P., Tardy S., Benito E., Obrador A., Costa J. Occurrence of Ki-ras and p53 mutations in primary colorectal tumors. Oncogene. 1991 ; 6: 2121-2128. (Pubitemid 21924054)
13. Greene FL, Balch CM, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6 th ed. Chicago, IL: American Joint Committee on Cancer ; 2002.
14. Li AR, Chitale D., Riely GJ, et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn. 2008 ; 10: 242-248. (Pubitemid 351692167)
15. Sholl LM, Xiao Y., Joshi V., et al. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol. 2010 ; 133: 922-934.
16. Cohen SJ, Cohen RB, Meropol NJ Targeting signal transduction pathways in colorectal cancer-more than skin deep. J Clin Oncol. 2005 ; 23: 5374-5385. (Pubitemid 46206991)
17. Hilbe W., Dlaska M., Duba HC, et al. Automated real-time PCR to determine K-ras codon 12 mutations in non-small cell lung cancer: comparison with immunohistochemistry and clinicopathological features. Int J Oncol. 2003 ; 23: 1121-1126.
18. Milano G., Etienne-Grimaldi MC, Dahan L., et al. Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer. Ann Oncol. 2008 ; 19: 2033-2038.
19. Rego RL, Foster NR, Smyrk TC, et al. Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer. 2010 ; 102: 165-172.
20. Karapetis CS, Khambata-Ford S., Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008 ; 359: 1757-1765.
21. Yunxia Z., Jun C., Guanshan Z., Yachao L., Xueke Z., Jin L. Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer. BMC Med Genet. 2010 ; 11: 34.
22. Jeon CH, Lee HI, Shin IH, Park JW Genetic alterations of APC, K-ras, p53, MSI, and MAGE in Korean colorectal cancer patients. Int J Colorectal Dis. 2008 ; 23: 29-35.
23. Breivik J., Meling GI, Spurkland A., Rognum TO, Gaudernack G. K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location. Br J Cancer. 1994 ; 69: 367-371. (Pubitemid 24046565)
24. Kislitsin D., Lerner A., Rennert G., Lev Z. K-ras mutations in sporadic colorectal tumors in Israel: unusual high frequency of codon 13 mutations and evidence for nonhomogeneous representation of mutation subtypes. Dig Dis Sci. 2002 ; 47: 1073-1079. (Pubitemid 34439183)
25. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987 ; 327: 293-297. (Pubitemid 17075079)
26. Boughdady IS, Kinsella AR, Haboubi NY, Schofield PF K-ras gene mutations in adenomas and carcinomas of the colon. Surg Oncol. 1992 ; 1: 275-282.
27. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990 ; 61: 759-767.
28. Bazan V., Migliavacca M., Zanna I., et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol. 2002 ; 13: 1438-1446.
29. Al-Mulla F., Going JJ, Sowden ET, Winter A., Pickford IR, Birnie GD Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. J Pathol. 1998 ; 185: 130-138. (Pubitemid 28270924)
30. Bell SM, Scott N., Cross D., et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology. 1993 ; 104: 57-64. (Pubitemid 23040006)
31. Laurent-Puig P., Olschwang S., Delattre O., et al. Association of Ki-ras mutation with differentiation and tumor-formation pathways in colorectal carcinoma. Int J Cancer. 1991 ; 49: 220-223.
32. Lee JC, Wang ST, Lai MD, Lin YJ, Yang HB K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers. Anticancer Res. 1996 ; 16: 3839-3844.
33. Andersen SN, Lovig T., Breivik J., et al. K-ras mutations and prognosis in large-bowel carcinomas. Scand J Gastroenterol. 1997 ; 32: 62-69. (Pubitemid 27026469)
34. Dix BR, Robbins P., Soong R., Jenner D., House AK, Iacopetta BJ The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer. 1994 ; 59: 747-751.
35. Hirvikoski P., Auvinen A., Servomaa K., et al. K-ras and p53 mutations and overexpressions as prognostic factors in female rectal carcinoma. Anticancer Res. 1999 ; 19: 685-691. (Pubitemid 29168316)
36. Samowitz WS, Curtin K., Schaffer D., Robertson M., Leppert M., Slattery ML Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev. 2000 ; 9: 1193-1197.